Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor

E. Pakkanen, D. Kalfert, M. Ahtiainen, M. Ludvíková, T. Kuopio, I. Kholová

. 2022 ; 130 (5) : 276-283. [pub] 20220313

Jazyk angličtina Země Dánsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018503

Grantová podpora
Tampere Tuberculosis Foundation
Pirkanmaa Cancer Foundation
Charles University Research Fund

Programmed cell death ligand (PD-L1)/PD-1 expression has been studied in a variety of cancers and blockage of PD-L1/PD-1 pathway is a cornerstone of immunotherapy. We studied PD-L1/PD-1 immunohistochemical expression in 47 thyroid gland specimens in groups of (1) Hashimoto thyroiditis (HT) only; (2) HT and follicular epithelial dysplasia (FED); and (3) HT, FED, and papillary thyroid carcinoma (PTC). PD-1 positivity was found in immune cells, namely in lymphocytes, macrophages, and plasma cells with mean values for lymphocytes and macrophages 9% in HT group, 4% in FED group, and 4% in PTC group. PD-L1 positivity was identified in both immune cells and in the normal epithelial cells. In the HT group, mean PD-L1 staining on immune cells was 6%, in FED group 5%, and in PTC group 7%. The mean PD-L1 staining on the epithelial cells in the inflammatory parenchyma was 11.7% in HT, 13.4% in FED, and 8.3% in PTC group. The mean PD-L1 staining of FED foci was 47.2% in FED group and 33.6% in PTC group. The mean tumor proportion score (TPS) was 10.4%, and the mean combined positive score (CPS) was 15.5. At the moment, PTC is not a target of immunotherapy. However, understanding the complex issue of concurrent inflammation and autoimmunity can importantly influence the cancer treatment in future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018503
003      
CZ-PrNML
005      
20220804134820.0
007      
ta
008      
220720s2022 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/apm.13218 $2 doi
035    __
$a (PubMed)35238073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Pakkanen, Emma $u Pathology, Fimlab Laboratories, Tampere, Finland $u Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
245    10
$a PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor / $c E. Pakkanen, D. Kalfert, M. Ahtiainen, M. Ludvíková, T. Kuopio, I. Kholová
520    9_
$a Programmed cell death ligand (PD-L1)/PD-1 expression has been studied in a variety of cancers and blockage of PD-L1/PD-1 pathway is a cornerstone of immunotherapy. We studied PD-L1/PD-1 immunohistochemical expression in 47 thyroid gland specimens in groups of (1) Hashimoto thyroiditis (HT) only; (2) HT and follicular epithelial dysplasia (FED); and (3) HT, FED, and papillary thyroid carcinoma (PTC). PD-1 positivity was found in immune cells, namely in lymphocytes, macrophages, and plasma cells with mean values for lymphocytes and macrophages 9% in HT group, 4% in FED group, and 4% in PTC group. PD-L1 positivity was identified in both immune cells and in the normal epithelial cells. In the HT group, mean PD-L1 staining on immune cells was 6%, in FED group 5%, and in PTC group 7%. The mean PD-L1 staining on the epithelial cells in the inflammatory parenchyma was 11.7% in HT, 13.4% in FED, and 8.3% in PTC group. The mean PD-L1 staining of FED foci was 47.2% in FED group and 33.6% in PTC group. The mean tumor proportion score (TPS) was 10.4%, and the mean combined positive score (CPS) was 15.5. At the moment, PTC is not a target of immunotherapy. However, understanding the complex issue of concurrent inflammation and autoimmunity can importantly influence the cancer treatment in future.
650    _2
$a antigeny CD274 $x metabolismus $7 D060890
650    12
$a papilární karcinom $x metabolismus $x patologie $7 D002291
650    12
$a Hashimotova nemoc $7 D050031
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD279 $7 D061026
650    _2
$a papilární karcinom štítné žlázy $x metabolismus $x patologie $7 D000077273
650    12
$a nádory štítné žlázy $x patologie $7 D013964
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kalfert, David $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, University Hospital Motol, Charles University, Prague 5, Czech Republic
700    1_
$a Ahtiainen, Maarit $u Department of Education and Research, Hospital Nova of Central Finland, Jyväskylä, Finland
700    1_
$a Ludvíková, Marie $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Plzen, Czech Republic
700    1_
$a Kuopio, Teijo $u Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland $u Department of Pathology, Central Finland Health Care District, Jyväskylä, Finland
700    1_
$a Kholová, Ivana $u Pathology, Fimlab Laboratories, Tampere, Finland $u Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
773    0_
$w MED00009218 $t APMIS : acta pathologica, microbiologica, et immunologica Scandinavica $x 1600-0463 $g Roč. 130, č. 5 (2022), s. 276-283
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35238073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134814 $b ABA008
999    __
$a ok $b bmc $g 1822203 $s 1169746
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 130 $c 5 $d 276-283 $e 20220313 $i 1600-0463 $m APMIS. Acta pathologica, microbiologica et immunologica Scandinavica $n APMIS $x MED00009218
GRA    __
$p Tampere Tuberculosis Foundation
GRA    __
$p Pirkanmaa Cancer Foundation
GRA    __
$p Charles University Research Fund
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace